An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection

摘要: Erythropoietin (Epo) was once thought to act exclusively in the formation of red blood cells. As recently reviewed by Smith et al. [Cardiovasc. Res. 59 (2003) 538-548], Epo can also within cardiovascular system with effects thrombosis and hypertension as well actions on platelets, vascular endothelium smooth muscle, myocytes heart. Here, protect neuronal cells brain are first evaluated parallel cardioprotection then drawn. Thus, recent reports receptor (EpoR) expression cardiac myocytes, it could be predicted that initiates direct protective signalling events. This is supported five independent studies published 2003 showing protects following ischemia/reperfusion. Importantly, these have been observed vitro vivo. The former suggests prevent myocyte death independently its cell number or other than myocytes. latter demonstrates potential for treatment heart post-infarction, decreasing numbers apoptotic limiting infarct expansion attenuating post-infarct deterioration haemodynamic function. These beneficial should stimulate further research into Epo.